Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Organisation › Details

Wilex AG

WILEX is a biopharmaceutical Company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malig-nant tumours in the body. The portfolio includes both drug and medical product candidates ranging from research to late stage clinical development. Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The company's strategy is to develop WILEX into a commercially successful biopharmaceutical company with a broad portfolio of new drugs and medical products for the treatment of cancer. *

 

Period Start 1997-10-01 established_pre
Period End 2017-10-18 renamed
  Group Heidelberg Pharma (Group)
  Today Heidelberg Pharma AG (FSE: WL6)
  Predecessor Wilex Biotechnology GmbH
  Successor Heidelberg Pharma AG (FSE: WL6)
Products Industry cancer drug
  Industry 2 antibody-drug conjugate (ADC)
Persons Person Schmidt-Brand, Jan (Wilex 201404– CEO before CFO + Heidelberg Pharma 200109– CEO + CFO)
  Person 2 Wilhelm, Olaf Georg (Therawis 201405– Managing Director before Wilex 2001–201403 CEO)
     
Region Region München (Munich)
  Country Germany
  Street 10 Grillparzerstr.
  City 81675 München
  Tel +49-89-413138-0
    Address record changed: 2018-07-24
     
Basic data Employees C: 51 to 100 (2016-11-30)
  Currency EUR
  Annual sales 2,743,458 (income, total, consolidated (2015/16) 2016-11-30)
  Profit -6,389,034 (2016-11-30)
  Cash 5,500,000 (2017-05-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Heidelberg Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top